Calcium alpha-ketoglutarate,
does it really help with Reduction in biological age and lifespan extension?
research showsNo human efficacy result is available to judge Ca-AKG alone for reducing biological age or extending lifespan. The 42-person report of an approximately eight-year reduction was an uncontrolled retrospective analysis of Rejuvant, which combines Ca-AKG with vitamins, while the pure Ca-AKG ABLE RCT has published only a protocol and recruitment report. General AKG use was not significant in the 4,260-person cross-sectional dataset, so the judgment is deferred.
ads claimMarketing links lower DNA-methylation-clock values to reversal of actual age and lifespan extension. Current human data concern a calculated biological-age surrogate, not disease incidence, functional independence, mortality, or lifespan.
Useful facts when choosing a product
- The observational studies evaluated a delayed-release combination containing Ca-AKG and vitamins.
- The retrospective before-and-after analysis included 42 people with about seven months of average use.
- The planned ABLE RCT dose is delayed-release Ca-AKG 1 g/day.
- No result directly measuring human lifespan extension was found.
Chamgap Semantic Classification Code
Candidate index · review held
UNK.calcium-alpha-ketoglutarate.UNK.biological-age-and-lifespan-extension.reduce.baselineUnknown > Calcium alpha-ketoglutarate > Unknown > biological age and lifespan extension > Reduction claim > Within-group baseline comparison
An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.
What the research actually shows
Demidenko 2021 compared TruAge DNA-methylation age before and after four to ten months of Rejuvant, a combination of Ca-AKG and vitamins, in 42 people and reported an average reduction of about eight years, but the analysis was uncontrolled and retrospective. The Sandalova 2023 and Lim 2025 ABLE publications concern the protocol and recruitment of a pure Ca-AKG RCT, not efficacy results. In the Pabis 2026 cross-sectional cohort of 4,260 people, an association was observed for a delayed-release Ca-AKG combination, whereas general AKG use was not significant.
Why this is classified as ?
Positive observational evidence concerns a Ca-AKG-plus-vitamin combination, the pure Ca-AKG ABLE RCT has no efficacy result, and the association for general AKG was not significant; human efficacy for Ca-AKG alone is therefore ungraded.
Counterpoint. The association with DNA-methylation age remains a hypothesis for randomized follow-up. This judgment does not convert animal lifespan data into human lifespan evidence.
Rejudgment record. Reassessment (cross-check reflected) — Positive evidence is an uncontrolled retrospective analysis of a Ca-AKG-plus-vitamin combination; pure Ca-AKG has no ABLE efficacy result, and general AKG use was not significant cross-sectionally
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Demidenko O et al. 2021 | Retrospective single-arm before-and-after analysis | 42 | Links to Ponce de Leon Health and TruMe | TruAge DNA-methylation age | Calculated age fell by about eight years after roughly seven months, but there was no control group and the product was a combination. | Key |
| Sandalova E et al. 2023; Lim ZM et al. 2025 | Double-blind RCT protocol and recruitment-feasibility report | 120 | Lien Foundation; investigator advisory link to product company | DNA-methylation age, metabolic markers, and function | Only the design and recruitment results have been published; efficacy results were not available. | Supportive |
| Pabis K et al. 2026 | Cross-sectional observational cohort | 4,260 | Academic study with disclosed product-related interests | Nine-CpG age residual | Delayed-release Ca-AKG combination use was associated with a 1.8-year lower age residual, but general AKG use was not significant and healthy-user bias remains possible. | Supportive |
Receipt — 3 References
All 3 cited sources were verified for existence at the original page (as of 2026-07-11).
Final verification and publication gate: Codex · Evidence date: 2026-07-11 · Corrections: none
Cite this verdict
[Chamgap] Calcium alpha-ketoglutarate (Ca-AKG) x Reduction in biological age and lifespan extension — Evidence Grade ?. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/antioxidant-aging/calcium-alpha-ketoglutarate-biological-age-longevity/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.